
Power to the Patients · 2026-11-05 · 30 min
Key moments - from our scoring
Substance score
67 / 100
Five dimensions, 20 points each
Neuroscience drug development faces a fundamental measurement problem: traditional large-scale trials in conditions like Alzheimer's, autism, and ALS rely on subjective clinical scales prone to placebo effects and post-hoc analysis, leading to decades of failed programs despite promising preclinical biology. Craig Erickson describes how Spinogenics uses high-density EEG and computer-based performance testing to quantify brain functional changes in smaller, faster trials - de-risking go/no-go decisions before expensive Phase 3 programs. Meanwhile, Gabriel Vargas critiques the dominant amyloid hypothesis in Alzheimer's: despite 30+ years of research and hundreds of trials, anti-amyloid monoclonal antibodies (lecanemab, dabanemab) show impressive biomarker clearance but clinically insignificant cognitive benefits - worse than 30-year-old cholinesterase inhibitors like Aricept. Vargas proposes adrenergic system targeting via beta-2 agonists (clenbuterol) paired with peripheral-restricted beta blockers (nadolol) to avoid systemic side effects, enabling rapid symptomatic relief plus a mechanistic rationale for disease modification through inflammation and autophagy effects. The episode addresses why pharma hasn't adopted these objective markers - inertia and failed trials - and positions biomarker-driven, smaller-scale studies as a credible de-risking strategy for future approval.
Hosted by Brandon Li. The show scores 87.0/100 on substance across its analysed episodes. See the full show profile.
Traditional trials enroll large patient cohorts with subjective outcome measures, creating placebo effects and incentivizing post-hoc analysis of secondary measures rather than quantifying actual brain functional change, leading to false negatives or uninterpretable results.
Spinogenics uses high-density EEG and computer-based performance testing to objectively measure brain functional changes in smaller cohorts (e.g., 10 patients vs. 100+), enabling faster go/no-go decisions before large Phase 3 trials.
No; while lecanemab and dabanemab are highly effective at clearing amyloid plaques (shown by biomarkers), their cognitive benefit is minimal - below 0.5 CDR sum of boxes points, below the minimally clinically important difference and worse than Aricept (a 30-year-old cholinesterase inhibitor).
Clenbuterol is co-dosed with nadolol, a peripheral-restricted beta blocker that blocks systemic effects (tachycardia, tremor, glucose release, hypokalemia) while allowing clenbuterol to reach the brain for cognitive and mood effects.
The facial expression recognition test, developed by Katherine Harmer at Oxford, measures whether patients can identify happy faces; depressed patients score ~40% vs. 70% in controls, and improvement on this test within 1-2 weeks predicts antidepressant response via the emotional processing hypothesis.
Our reviewer’s read on each dimension, with quotes from the episode.
Strong technical substance on trial de-risking with quantitative biomarkers, the amyloid-efficacy gap, and a peripherally-restricted beta-blocker pairing mechanism, though value for a general B2B operator is narrow and a large block of content is verbatim duplicated.
we did high density EEG study to see what brain electrical activity change was happening
we've coupled our beta 2 agonist with a peripherally restricted beta blocker, nadalol
Genuinely contrarian stance that approved anti-amyloid drugs are not meaningfully disease-modifying, plus a first-principles argument for placebo-resistant objective endpoints over large symptomatic trials.
I don't believe that. I don't think we're seeing disease modification
how can we use biologic markers of brain function that are quantitative and placebo resistant
Both guests are credible practitioners: one ran failed autism trials at Cincinnati Children's and leads Fragile X work, the other worked on amyloid programs at Roche and digital health at Amgen.
when I was at Roche, uh, back in 2008, 2009 and I was in Basel for three years at Roche headquarters
I've been involved, for example, in autism with every negative, double blind, placebo controlled, multisite, large scale trial
Dense with named drugs, mechanisms, and hard numbers - CDR sum-of-boxes thresholds, recognition rates, familial vs sporadic percentages - giving concrete evidence throughout.
What they got in their studies was slightly less than 0.5
about a 70% recognition uh rate, patients depressed will score about 40%
The host lands one genuinely probing challenge, but as a stitched 'best of' compilation most prompts are high-level lobs with little real-time follow-up or pushback.
If I may be difficult for a moment, this sounds ideal. Why doesn't everyone else do it this way
Let me just lob a high, uh, level question. Your way to start. Why synapses?
Computed from the transcript - who did the talking, and the words that came up most.
Neuroscience has one of the toughest track records in drug development. Large trials enroll hundreds of patients, struggle with placebo response, and often end with teams chasing subgroups in secondary endpoints. In this episode of Power to the Patients, host Brandon Li speaks with two experts who approach the problem from different angles. Craig Erickson, a Psychiatrist at Cincinnati Children's and Chief Medical Advisor at Spinogenix, explains how high-density EEG, transcranial magnetic stimulation, and computer-based cognitive testing can show whether a drug is doing anything at all. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, shares his view of the amyloid hypothesis he once believed in, the gap between biomarker results and patient benefit, and how CuraSen reaches the brain's adrenergic system without the usual effects on the heart and metabolism.
Transcribed and scored by The B2B Podcast Index.
Speaker A: Hi, you're listening to Power to the Patients, hosted by Brandon Lee, the podcast for leaders and innovators in pharma and biotech. In each episode, Brandon, the co founder of Power, cuts through the noise to bring real world insights on modern drug development, clinical operations and the science that drives breakthrough therapies. Because at the end of the day, it's about patients, not just molecules and markets. If you enjoy the podcast, make sure to subscribe and leave a five star rating on Apple, Spotify or wherever you get your podcasts. Let's get started.
Speaker B: We have spent decades trying to understand the brain, but some of the biggest questions in neuroscience remain unanswered. Are we targeting the right biology? Why have so many promising treatments struggled to translate? And what if the next breakthrough isn't about slowing disease but actually restoring how the brain functions? I'm your host Brandon Lee and in this best of episode, we're bringing together insights from Craig Erickson and Gabriel Vargas to explore how we measure the brain, rethink treatment and push the boundaries on what's possible. Let's get into it. What are we still getting wrong about the brain? Tell me a little bit more about like the from to observation that you, you see and how that's maybe different from like the, let's call it, traditional way of doing things.
Speaker C: I think the traditional way of doing things is very large scale. So you're going to go into Fragile X or AUT or ALS or Alzheimer's and you're going to dose a whole lot of patients and hem and ha about are we seeing, are we seeing clinical change? You get a lot of placebo effect, you end up, and we've done this a lot in neurodevelopmental disorders. You catch yourself with post hoc comparisons where you're like, well, we thought we were using this scale, but this tertiary or secondary measure looks like it's changing in a subgroup and you end up chasing these things. And the different approach from sort of beginning to end with spinogenics is it's like if we're going to enter a disease and a disorder, we're going to look at for example, what we did in Fragile X, we did computer based performance testing and we did high density EEG study to see what brain electrical activity change was happening, if it rescued known abnormalities in the disorder and if in parallel patient performance on cognitive testing improved. In als, for example, there's bringing in EEG and transcranial magnetic stimulation as exemplars to look at brain functional change along with more traditional observational Measures. That's just a different approach of being able to make go or no go decisions based on highly quantitative data. It enables you to do studies very quickly, burden a smaller number of patients and then sort of launch from there.
Speaker B: I think one of the topics that I wanted to talk about was the difference between disease modification and kind of symptomatic approaches. At least in the first half of this discussion it sounded to me we were talking mostly about symptomatic treatments or memory in particular, maybe encoding memory like while taking one of these agents. How do you think about the difference between the opportunity here to modify progression or modify the nerve, uh, generation versus uh, just treating, uh, kind of things. That's a big topic I think of discussion in general. You'll see different points of view on this. I had different points of view of this on the podcast. I think symptomatic treatment is very important. Let's talk about Alzheimer's disease and just narrow it down to that to begin with. Patients with Alzheimer's disease, a variety of neurological
Speaker D: neuropsychiatric disorders, there's kind of a neurological deficit, but they also have apathy and depression and agitation. Is neuropsychiatric. If you have a drug that actually treats these, even though it's not important, disease modifying, it's something that would be beneficial to patients. It's something that I think is not trivial. If you're able to allow these patients to be independent for a long period of time, you avoid them. Going into assisted living, skilled nursing facilities and situations like that I think is a very positive. Currently there's a lot of energy being spent and money being spent on the development of uh, anti amyloid therapy. So the amyloid hypothesis is what, probably 30, 40 years old by now. There have been by now several hundred trials looking at anti amyloid therapy and the hypothesis for the involvement of uh, amyloid, a lot of it is both on biochemistry but also in genetic bounds that there are genetic mutations in the processing of uh, a beta, uh, and that uh, is correlated with early onset familial Alzheimer's disease. So familial Alzheimer's disease is a small subset of uh, the sporadic. So if you look at the um, ad in general, about less than about 10% familial, but 90 plus percent are going to be non familial. So the late onset Alzheimer's disease people again at Patch 65, 70 or so, as opposed to the familial lady in which you, you see patients getting the disorder, the 30s and the 40s. So there's a lot of genetic data with the involvement of the amyloid pathway, if you will. So when is at Roche? Uh, back in 2008, 2009 and I was in Basel for three years at Roche headquarters. And one of the programs I worked on was cantineraba, which is one of the early xenolobodies developed for amyloid therapies. So I was very involved in that. I was very much a believer that the amyloid hypothesis made a lot of sense. That the reason a lot of these drugs hadn't worked is because we were going too late in the disease when people already had basically their brains had already been severely affected by years of having Alzheimer's disease. So what needed to be done is to go earlier in the process with anti amyloid therapy and that would be a much uh, better situation. But it has been tried now to go even earlier going into formal ad to go into MCI prodromal space and we still don't see a lot of efficacy. Probably the most recent ones have been lecanemab and dinamide, uh, both are approved by the fda. And these are amyloid therapies. They're monoclonal antibodies that target amyloid so they remove amyloid plaques. If you look at the biomarker you see that either by using CSF for blood or imaging, using PECT imaging of amyloid, you see. But these drugs are extremely effective in the removal of plaques and removal of amyloid, but their cognitive impact is limited. So there's this concept of minimally clinically important difference in cid, it's basically defined as what is the smallest difference you can have in the clinical setting that will be relevant to the patient so that the patient will notice I'm doing much better than I was before I took this. So NCID in the primary endpoint that uh, lecanemab used, which was a CDR summit boxes, the minimally clinically important difference is about 0.5 to 1 point in the CDR summit boxes. What they got in their studies was slightly less than 0.5. So it's really a very tiny effect. It's actually not even as good as Aricept, which was a uh, cholinesterase inhibitor, small drug that was developed 30 plus years ago. So if you look at the biomarker data, it's impressive.
Speaker B: Get
Speaker D: rid of that. If you look at the cognition data, it's not impressive. It's really not giving you that much of an effect. So there's discussion that what we're looking at with anti amyloid therapist disease Modification therapy. I don't believe that. I don't think we're seeing disease modification and you have these patients on for 18 months before you really begin to see that difference. So it would be wonderful to have disease modifying therapy. I don't think we have it with amyloid. With our mechanism of action we've targeted the adrenergic system. It's very fast onset so you can see symptomatic therapy early on. But there's also a very strong rationale for why you might see disease modification because uh, uh, it has a positive effect on inflammation, it has a positive effect on autophagy, which are all components that are relevant to disease modification. So our hypothesis is that if we were to treat patients for a longer period of time than we've been able to treat them so far, we begin to see these disease modifying effects ah, and biomarkers and such. So so far we've, the trials we've conducted have been uh, short the mid two week trials in which we've seen cognitive effects and also we've seen effects on mood using a biomarker for antidepressant effect. So antidepressants. One hypothesis for how antidepressants work is the emotional processing hypothesis, which it is the hypothesis you're depressed because you have a negative emotional bias. In other words, when you look at the world you interpret uh, things that you neither interpret as neutral or happy, you interpret it as sad. And that is captured really nicely in the uh, test called the facial expression recognition test. This comes from work from uh, Kathryn Harmer at Oxford. She's been developing this for last 20 years or so. So there's a lot of data showing that the facial expression recognition task is actually predictive antidepressant response. Because the hypothesis is you are able to change the negative emotional bias that occurs early on in the antidepressant treatment. Uh, and that has to happen before you actually get relief from depression. First you have to change the way you process the world. And once you've done that you can get better. And that comes on about two weeks, one to two weeks after treatment. And that we captured in our study looking at happy faces. So if you look at interested, if you show a depressed patient a happy face, they'll have trouble distimation back as a happy face. You and I were looking and say oh yeah, that's a happy fix. With about a 70% recognition uh rate, patients depressed will score about 40% which is what we saw in our job. And then when we gave them medication it actually returned Them to essentially normality.
Speaker B: What happens when we target the underlying biology instead of just treating symptoms? Let me just lob a high, uh, level question. Your way to start. Why synapses?
Speaker C: I think from a brain functional standpoint, we have millions of brain cells, neurons that need to connect. And it's those connections between cells that really form a common thread across a number of brain disorders. So neurodegenerative disorders, things like ALS and Alzheimer's, significant severe mental illness like schizophrenia and neurodevelopmental disorder. So we see a lot of common threads that signaling from cell to cell at these synapses that are really connections. And they have both what's called a pre and a postsynaptic component. So the cell that's trying to get the message down the chain in a way. And so that chain, those links tend to break down in different ways, leading to a lot of different brain pathology. Again, as broad as from ALS and Alzheimer's to, I study Fragile X, which is a genetic cause of autism. A common link is this synaptic or these connections that degenerate and break down for different biologic reasons. If we can restore those connections, we can really have a more functional brain.
Speaker D: That's a good question, I think. So let me give you a little bit more perspective on how we're targeting this. As I was mentioning earlier, if you take adrenergic agents, and the ones we've been focusing are, uh, two types. So there are nine different receptors for the adrenergic system aren't particularly efficacious. And, uh, so beta 2 adrenergic receptor, which is helpful on asthma. So all the inhalers, albura inhalers are worked through the beta 2 adrenergic receptor and the alpha 1 adrenergic receptor. And I'll talk about those two separate. So the beta 2. So if you give somebody an oral beta 2 agonist, clenbuterol is a good example. Clenbuterol is approved in, uh, Europe and Germany, in particular for reactive airways disease. So asthma, like in which your bronchi constrict. So a beta 2 agonist will relax a bronchi, allow you to breathe. So if you give somebody a beta 2 agonist, that helps their asthma symptoms. But if you give it systemically, clenbuterol is a neural agent. So if you give systemic, you get an increase in heart rate, you can get palpitations, you can get tremor, you get, uh, glucose release, you get a drop in potassium. So a lot of peripheral effects that you don't want if you're developing a drug that is targeting the cns. So what we have done at Kirsten is we've coupled our beta 2 agonist with a peripherally restricted beta blocker, nadalol. So nadalol does not get in the pain and so you can co dose them so that you add the clombuterol and the nadalal together. So the nadal blocks all the peripheral effects of clenbuterol. So you don't get the increase in heart rate, you don't get the increase in uh, glucose, you don't get the drop in potassium and that allows you to target the brain. So that's the way we're thinking about the use of beta 2 ions. So we're using Planbiro, which has been in the market for about 40 years. But we're also developing our novel chemical agents as well, also coupled with Nadalm. Um, and the idea is to develop a fixed dose formulation for those compounds. So you give a single tablet and that has both the beta blocker and the beta 2 agonist. So it selectively targets the brain. So once you've developed that, uh, what are the indications that would be helpful? So as I was mentioning, because of the essential fundamental importance of the adrenergic system and original fight or flight and all the things that come along with it, attention, memory, but also things like apathy and impulsivity are very relevant to the adrenergic system. So disorders that have issues with depression, cognition, arousal, apathy, impulsivity. So you can have. There are a lot of psychiatric disorders that have that, also a lot of neurodegenerative disorders that have that. So Alzheimer's disease has issues of uh, apathy, so does Parkinson's disease and Alzheimer's impulsivity. So these are all potential targets for adrenergic agent and beta NCU adrenergic agent. The other advantage of using this approach is that it is a direct agonist. So if you think about the way that say you're developing antidepressant SSRIs, neuroadragent re mtic inhibitors, those are all indirect agonists. By that I mean that the mechanism action requires there to be endogenous levels of whatever neurotransmitter you're stimulating. So for SSRI you have to have serotonin available. If you don't have serotonin available, inhibiting the re empty pump does nothing because you don't have endogenous lobes. Same thing with acetylcholinesterase inhibitors which were developed for Alzheimer's disease back in the 90s. Things like donepezil, they require dodgeness levels of the neurotransmitter to be present. Same thing with neurodrenergically empty neighbors. If you don't have it, dodges levels of neuroadrenaline. It's not going to be effective. We bypass that by going directly to the downstream M postsynaptic receptors.
Speaker E: Why has neuroscience been so difficult to turn into effective treatments?
Speaker B: If I may be difficult for a moment, this sounds ideal. Why doesn't everyone else do it this way, uh, using EEGs and these more objective markers?
Speaker C: It's a great question. When I got into this work 10 or 12 years ago with objective markers, I scratched my head too. But I had a career of negative trials. I mean, I like to say I've been involved, for example, in autism with every negative, double blind, placebo controlled, multisite, large scale trial. We just failed after failed after failed after failure. And that made me reconsider our approach because I would take treatments that in clinic, open label treating off label use of medicine. Two thirds of patients in clinic would seem to be, quote, improved, whatever that meant. And then we would enroll 100 or 200 kids with autism as an example. And we would never beat placebo and we would never have quantitative measures of what was the drug was doing to affect an individual. So we shift and I think it's not a typical way for pharma to approach a lot of new indications. And I think it really is state of the art, newer de risking strategy of future larger phase trials to make go or no go decisions. That's really what it is. And with the 10 men in fragile X that we enrolled in the spinogenics trial here at Cincinnati Children's with Fragile X syndrome, if we would have seen absolutely nothing, I would have said, look, this may not make sense to move forward, but can we figure this out in six months versus two years in 10 men versus 100 patients? And I think the answer is yes. So I think we're trying to change the tone and approach in neuroscience trials to de risk things. And I only came out of that through massive failures, almost two decades of failed trials for core symptoms of autism. We have to do things better. So I really move to how can we use biologic markers of brain function that are quantitative and placebo resistant. And I think that has legs. We're seeing a lot more interest in it in using quantitative EEG and uh, analysis type we call source localization, that you just get a lot more Usable data from small samples. But the proof will be in the future, right? It'll be in can these informed go or no go decisions result in approval. So that is to be shown to your point Brandon, we need to show that. But I think the early returns are, we can at very least discern this is showing good target engagement. This is doing absolutely nothing and help the directions and the future decisions.
Speaker D: That's a big topic I think of discussion in general. You'll have different points of view on this. I had different points of view of this on the
Speaker B: podcast.
Speaker D: I think symptomatic treatment is very important. Let's talk about Alzheimer's disease and just narrow it down to that to begin with. Patients with Alzheimer's disease, a variety of neurological and neuropsychiatric disorders. There's kind of a neurological deficit, but they also have apathy and depression and agitation. Is neuropsychiatric. If you have a drug that actually treats these, even though it's not important, disease modifying, it's something that would be beneficial to patients. It's something that I think is not trivial. If you're able to allow these patients to be independent for a long period of time, you avoid them. Going into assisted living, skilled nursing facilities and situations like that I think is a very positive. Currently there's a lot of energy being spent and money being spent on the development of uh, anti amyloid therapy. So the amyloid hypothesis is what, probably 30, 40 years old by now. There have been by now several hundred trials looking at anti amyloid therapy and the hypothesis for the involvement of ah, amyloid. A lot of it is both on biochemistry but also in genetic grounds that there are genetic mutations in the processing of a beta and that uh, is correlated with early onset of familial Alzheimer's disease. So familial Alzheimer's disease is a small subset of uh, the sporadic. So if you look at the ad in general, about less than about 10% familial, but 90 plus percent are going to be non familial. So it'll be late onset Alzheimer's disease. People again at patches, 65, 70 or so as opposed to the familial ad in which you see patients getting the disorder the 30s and the 40s. So there's a lot of genetic data with the involvement of the amyloid pathway if you will. So when I was at Roche, uh, back in 2008, 2009, I was in Basel for three years at Roche, had headquarters and one of the programs I worked on was Cantameraba which is one of the early xenolibods developed for amyloid therapies. So I was very involved in that. I was very much a believer that the amyloid hypothesis made a lot of sense, that the reason a lot of these drugs hadn't worked is because we were going too late in the disease when people already had basically their brains had already been severely affected by years of having Alzheimer's disease. So what needed to be done is to go earlier in the process with anti amyloid 1 therapy. And that would be a uh, much better situation. But it has been tried now to go even earlier going into phenol AD to go into MCI prodromal space and we still don't see a lot of efficacy. Probably the most recent ones have been lecanemab and dabanemab. Both are approved by the fda. And these are amyloid therapies. They're monoclonal antibodies that target amyloid, so they remove amyloid plaques. If you look at the biomarker you see that um, either by using CSF or blood or imaging, using pecked imaging of amylog, you see that these drugs are extremely effective in the removal of plaques and removal of amyloid, but their cognitive impact is limited. So there's this concept of minimally clinically important difference in cid. It's basically defined as what is the smallest difference you can have in the clinical setting that will be relevant to the patient so that the patient will notice I'm doing much better than I was before I took this. So NCID in the primary endpoint that uh, Lecanemap used, which was a CDR summer boxes. The minimally clinically board difference, about 0.5 to 1 point in the CDR summit boxes. What they got in their studies was slightly less than 0.5. So it's really a very tiny effect. It's actually not even as good as Aricept, which was a, uh, cholinesterase inhibitor small drug that was developed 30 plus years ago. So if you look at the biomarker data it's impressive. If you look at the cognition data, it's not impressive. It's really not giving you that much of an effect. So there's discussion that what we're looking at with anti amyloid therapy is disease modification therapy. I don't believe that. I don't think we're seeing disease modification and you have these patients on for 18 months before you really begin to see that difference. So it would be wonderful to have disease modifying therapy. I don't think we have it with Envelope with our mechanism of action targeting the adrenergic system. It's very fast onset. So you can see symptomatic therapy early on. But there's also a very strong rationale for why you might see disease modification. Because, uh, it has a positive effect on um, inflammation, it has a positive effect on autophagy, which are all components that are relevant to disease modification. So our hypothesis is that if we were to treat patients for a longer period of time than we've been able to treat them so far, we'd begin to see these disease modifying effects, uh, and biomarkers and such. So so far the trials we've conducted have been uh, short, the bacteria weak trials in which we've seen cognitive effects and also we've seen effects on mood using a biomarker for antidepressant effect. So antidepressants. One hypothesis for how antidepressants work is the emotional processing hypothesis, which it is the hypothesis you're depressed because you have a negative emotional bias. In other words, when you look at the world, you interpret uh, things that you neither interpret as neutral or happy, you interpret it as sad. And that is captured really nicely in the uh, test called the facial expression recognition test. This comes from work from uh, Katherine Harmer at Oxford. She's been developing this for the last 20 years or so. So there's a lot of data showing that the facial expression recognition task is actually predictive of ah, antidepressant response. Because the hypothesis is you are able to change the negative emotional bias that occurs early on in the antidepressant treatment. That has to happen before you actually get relief from depression. First you have to change the way you process the world. And once you've done that, you can get better. And that comes on about two weeks, one to two weeks after treatment. And then that we captured in our study all looking at happy faces. So if you look at interested, if you show a depressed patient a happy face, they'll have trouble distinguishing back as a happy face. You and I would look at it and say, oh yeah, that's a happy face. With about a 70% recognition, uh, rate. Patient who's depressed will, will score about 40%, which is what we saw in our trial. And then when we gave the medication, it actually returned them to essentially normality.
Speaker E: What is the next breakthrough in neuroscience?
Speaker B: In closing here, I've got a few questions for you. Just start like continue to look into the future. So for the patients, caregivers, clinicians, uh, investigators and investors that are listening, what should they know or watch for on the horizon and be excited about. As far as the spinogenics programs go.
Speaker C: Well, I think Spinegenics and Fragile X, they want to look to the near term chronic dosing work and first really focusing on this male population and then expanding. And I think it's the number one preclinically validated and really the only mechanism within human positive target engagement data out there to get a lot of attention in the near term. With the work with 302 in ALS, Alzheimer's and schizophrenia, there's going to be some long term treatment data coming out in the near term that I think Spinogenics and I are excited about. And I think the sky's the limit for that concept. And I think spinogenics is first in the space of altering synaptic spine morphology, as we said earlier, in ways that can really restore brain function and restore it in a way that's quantifiable. So I think that is very exciting. And again, which disorder do you Pick first with 302 is to be determined, but it is broadly applicable. I'm a psychiatrist. If we had non antipsychotic approaches to schizophrenia that could restore positive and negative symptoms and potentially cognition, that's massively game changing. And we know how devastating ALS is and Alzheimer's and the minimal effects of available pharmacotherapy. So I think there's a lot of excitement to follow there. I think the stakeholders are really excited about it and I think Spinogenics has really embraced the stakeholder voice and been very open to extended open label treatment periods and thinking about EAPs and expanding access very early with their development program. So I really commend them for that and understanding that individuals with these devastated diseases, drug approval is really slow and we all know that. And are there ways to sort of to reach a common ground? And they're doing that and I think that's really important.
Speaker D: So I think that's something that's really exciting. Uh, another area that I'm interested for many years, digital health technologies. Sure. When I was at Amgen, I was in charge of incorporating digital health technologies into our wider group, which was, uh, the medical sciences group, which is in charge of all the early nonprofit with the idea of how do we leverage these technologies? Because when you conduct a clinical trial in neurodegeneration, these will be three month long, six month long trials and you see them maybe twice a month, but you don't know what's happening at home. Now if you had a digital wearable device, some kind of digital health technology, that you could actually measure what's happening at home as opposed to when they come in for the checkup their sosma, you just have so much more information and you have information in the wild, so to speak, and where they're really their home environment, which is much less artificial than a clinic setting. You have to draw to major research laboratories somewhere. I think there's a lot of potential there. It's been a lot of activities in the uh, editorial board of Digital Biomarkers, which, um, we publish a lot of the work that's being done and so I get to read a lot of papers. And what I see happening is a lot of smaller groups are trying to do the same thing and develop uh, digital health technologies for a given subset of indication, but it's the same technology somebody else is developing for slightly different indications. So what I wish there's been more harmony and larger consortia that are developing. And this is your sleep wearable, this is your Tigger of your wearable. This is your 6 minute walk test wearable. This is so on and so forth. Get them um, FDA approved, become the gold standard. You can use them as primary endpoint because there's a lot of value in that. And then psychiatry is interesting because you can also leverage smartphones and you know, how much contact you're having, how much you're participating, texting, phone calls, etc.
Speaker A: That wraps up today's episode of Power to the Patients. If you found this conversation valuable, make sure to follow or subscribe so you don't miss the next one. For more insights on drug development, clinical operations and the future of pharma and biotech, connect with us on LinkedIn. Thanks for listening and uh, see you next time.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.